Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort - Université de Picardie Jules Verne
Article Dans Une Revue Clinical Microbiology and Infection Année : 2023

Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort

1 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
2 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
3 CIC 1425 - Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique
4 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
5 CIC 1418 - CIC - HEGP
6 DMU CARTE - CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris]
7 HEGP - Hôpital Européen Georges Pompidou [APHP]
8 UGSF - Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576
9 Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
10 CIC - Centre d’Investigation Clinique [Tours] CIC 1415
11 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
12 CHU Reims - Hôpital universitaire Robert Debré [Reims]
13 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
14 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
15 BRM - ARN régulateurs bactériens et médecine
16 CIC - Centre d'Investigation Clinique [Rennes]
17 CIC 1417 - CIC Cochin Pasteur
18 CHU Saint-Antoine [AP-HP]
19 MASCOT (UMR_S_942 / U942) - Marqueurs cardiovasculaires en situation de stress
20 Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
21 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
22 AP-HP - Hopital Saint-Louis [AP-HP]
23 Hôpital Foch [Suresnes]
24 AGIR - Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
25 Centre Hospitalier Gustave Dron [Tourcoing]
26 EAS - European Atherosclerosis Society [Göteborg, Sweden]
27 CHU Pointe-à-Pitre / Abymes [Guadeloupe]
28 UA UFR SM - Université des Antilles - UFR des sciences médicales Hyacinthe Bastaraud
29 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
30 CHBA - Centre hospitalier Bretagne Atlantique (Morbihan)
31 CIC - Antilles Guyane - Centre d'Investigation Clinique Antilles-Guyane
32 CHU de Martinique - Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique]
33 PCCEI - Pathogenesis and Control of Chronic and Emerging Infections
34 F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC)
35 CIC - CHU Bichat
36 LCE - Laboratoire Chrono-environnement (UMR 6249)
Odile Launay
  • Fonction : Auteur

Résumé

Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale <57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). Conclusions - One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.
Fichier principal
Vignette du fichier
Ghosn et al. - 2022 - Prevalence of post-acute COVID-19 symptoms twelve (1).pdf (469.33 Ko) Télécharger le fichier
Supplementary data Multimedia component 1.pdf (608.04 Ko) Télécharger le fichier
Supplementary data Multimedia component 2.pdf (821.92 Ko) Télécharger le fichier

Dates et versions

hal-03801797 , version 1 (21-02-2023)

Licence

Identifiants

Citer

Jade Ghosn, Delphine Bachelet, Marine Livrozet, Minerva Cervantes-Gonzalez, Julien Poissy, et al.. Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort. Clinical Microbiology and Infection, 2023, 29 (2), pp.254.e7-254.e13. ⟨10.1016/j.cmi.2022.08.028⟩. ⟨hal-03801797⟩
207 Consultations
354 Téléchargements

Altmetric

Partager

More